CURRICULUM VITAE David L. DeRemer, Pharm.D, FCCP, … · David L. DeRemer - CV 5 2015 PHRM 5210: Insights into Clinical Practice – 2 contact hours, ... 2012 Ahmed Al-Azayzih, Pharm.D

CURRICULUM VITAE

David L. DeRemer, Pharm.D, FCCP, BCOP November 2017

______________________________________________________________________________

GENERAL INFORMATION

Office Address: University of Florida College of Pharmacy

Department of Pharmacotherapy and Translational Research

HPNP 2302

Gainesville, FL 32610

Email: [email protected]

Telephone: Office: 352-273-6225

Fax: 352-273-6485

Present Position: Clinical Associate Professor

Assistant Director of Experimental Therapeutics and Incubator (ETI)

University of Florida College of Pharmacy

University of Florida Health Cancer Center

EDUCATION

1992-1996 B.S., Biology

University of Kentucky College of Arts and Sciences

1998-2002 Doctor of Pharmacy

University of Kentucky College of Pharmacy

POSTDOCTORAL TRAINING

2002-2003 Pharmacy Practice Residency (ASHP-Accredited)

University of Kentucky Chandler Medical Center

Director: Kelly Smith Pharm.D., BCPS, FASHP, FCCP

2003-2004 Hematology-Oncology Residency (ASHP-Accredited)


Director: Val Adams Pharm.D., FCCP, BCOP

2004-2005 Oncology Postdoctoral Fellowship

Drug Discovery/Development


Director: Val Adams Pharm.D., FCCP, BCOP

mailto:[email protected]

David L. DeRemer - CV

2

ACADEMIC RANK AND APPOINTMENTS

9/2006-6/2012 Clinical Assistant Professor

University of Georgia College of Pharmacy

Department of Clinical and Administrative Pharmacy

Clinical and Experimental Therapeutics (CET) Program

Augusta, GA

7/2012- 8/2017 Clinical Associate Professor


7/2013- 8/2017 Adjunct Clinical Associate Professor

Medical College of Georgia

Department of Medicine, Section of Hematology/Oncology

Augusta, GA

9/2017- present Clinical Associate Professor


Department of Pharmacotherapy and Translational Research

PROFESSIONAL LICENSURE AND BOARD CERTIFICATION

2002- current Kentucky Pharmacy Licensure (#012403)

2005- current Georgia Pharmacy Licensure (#022799)

2006- current Board of Pharmaceutical Specialties

Board Certified Oncology Pharmacist (#506006838)

Recertified by CE (2012)

PROFESSIONAL EXPERIENCE

1996-1998 Senior Lab Technician

University of Kentucky College of Medicine

Department of Microbiology & Immunology

Jesse Sisken, Ph.D. Laboratory

1999-2002 CVS Pharmacy Intern

Lexington, KY

2004-2005 Hematology/Oncology PRN Pharmacist

University of Kentucky Markey Cancer Center

Lexington, KY


3

2005-2006 Hematology/Oncology Clinical Specialist

Bone Marrow Transplant/Oncology Clinical Specialist

Medical College of Georgia (MCG Inc.)

Augusta, GA

2006- 2013 Inpatient Hematology/Oncology Clinical Specialist

Inpatient Bone Marrow Transplant/Oncology Clinical Specialist

Georgia Regents University Medical Center

(Formerly Georgia Health Sciences University and MCG Health)

Augusta, GA

2013- 2017 Outpatient BMT/Hematological Malignancies Clinical Specialist

Georgia Cancer Center

Augusta, GA

2017- present Assistant Director of the Experimental Therapeutics Incubator

University of Florida Health Cancer Center (UFHCC)

Gainesville, FL

TEACHING EXPERIENCE


Pharm.D. Curriculum

2018 PHA5784C Patient Care IV – 3 contact hours

Lecturer – Colorectal cancer screening

Active Learning – Colorectal Cancer

PHA5081C Complex Patients – 1 contact hour

Lecturer- Oncologic emergencies


Pharm.D. Curriculum

2006-2007 PHRM 3800: Clinical Applications - 8 contact hours, patient based learning

Course Coordinator

Facilitator – Rheumatoid arthritis

Facilitator – Multiple myeloma

Facilitator - Hypothyroidism

Facilitator – Coronary Artery Disease


4

Facilitator – Breast cancer

Facilitator – Crohn’s disease

2007-2008 PHRM 5210: Clinical Oncology Elective – 12 contact hours, interactive cases, s

seminars, experiential component

Course Coordinator

2007-2017 PHRM 5870: Pharmacotherapy II – 6 contact hours, interactive cases, team-

based learning

Course coordinator (2017)

Lecturer – Breast cancer (1 semester)

Lecturer – Bone marrow transplantation (3 semesters)

Lecturer – Growth factors (1 semester)

Lecturer – CINV (6 semesters, co-mentored PGY2 resident)

Lecturer - Systemic fungal infections (5 semesters)

Lecturer – Oncologic emergencies (2 semesters)

2007-2008 PHRM 5140: Clinical Skills Lab – 12 contact hours, facilitated labs with OSCEs

Co-Coordinator

2009- 2012 PHRM 4190: Cancer and Chemotherapy - 10-12 contact hours

Co-Coordinator

Lecturer – Chemotherapy dosing, delivery, terminology

Lecturer – Adverse events of chemotherapy and palliation

Lecturer – Prostate cancer

Lecturer – NHL/Hodgkin lymphoma

Lecturer – Pediatric malignancies

Lecturer - Chronic leukemias

Lecturer – Acute leukemias

Lecturer – Colorectal cancer

Lecturer – Lung cancer and mesothelioma

Lecturer – Disease related symptoms

2010 -2011 PHRM 5210: Landmark Clinical Studies in Oncology and Clinical Applications

Seminars, interactive cases, experiential- Elective course

Co-coordinator

2011-2017 PHRM 5920: Clinical Seminar- 3-5 contact hours/semester – student mentoring

2013- 2015 PHRM 5190: Anticancer therapeutics – 5-10 contact hours, didactic

Lecturer – see above (PHRM 4190)


5

2015 PHRM 5210: Insights into Clinical Practice – 2 contact hours, small group

interactive cases

2015 PHRM 5210: Resident Rounds- 12 contact hours, small group, didactic lectures

Course coordinator

2016-2017 PHRM 3520: Interpreting Clinical Lab Tests – 1 contact hour, didactic

Lecturer – Hematology: Red and White Blood Cells

2016 PHRM 3030: Essentials of Pharmacy Practice I – 8 contact hours, small group

recitation

2017 PHRM 3040: Essentials of Pharmacy Practice II – 8 contact hours, small group

recitation

2017 PHRM 4040: Essentials of Pharmacy Practice IV – 2 contact hours, skills lab

Skills Lab – Handling hazardous agents

2017 PHRM 5210: Integrated Patient Cases – 2 contact hours, cases and simulated

EMR

Experiential Experiences

Year Rotations Practice Site (s) Students- hours

2007- 2017 5901-5908 (APPE)

Inpatient Hematology/Oncology

BMT

Outpatient Oncology

8-10 students per year 150- 200 contact hours per rotation

2012- 2017 IPPE Oncology 8-12 students per year

Resident Graduate Curriculum

Year Rotations Format Graduate students- hours

2011-2017 PHRM 7210 Advanced Pharmacy Care

Small group discussion 5-7 students- 5 contact hours/year

2011-2017 (Fall semesters)

PHRM 7810 Pharmacy Care

Direct precepting 1-2 students- > 100 contact hours

2011-2017 PHRM 7910 Adv Pharmacy Care

Direct precepting >100 contact hours

2011- 2017

PHRM 7830 Residency Research

Research advising 1-2 students- > 100 contact hours

2011- 2017 PHRM 7840 Teaching Pharmacy Practice

Advising 1 students -> 10 contact hours


6

2011- 2017 PHRM 7940 Teaching Pharmacy Practice PGY2

Advising 1-2 students -> 10 contact hours

2012-2013 PHRM 7210 Special Topics PGY2 Oncology Residents

Interactive cases 10 contact hours

Medical College of Georgia College of Allied Health- Physician Assistant Program

2009-2015 Chemotherapy 101

Chemotherapy Induced Nausea-Vomiting

Format: Didactic lectures

Medical College of Georgia College of Nursing

2008-2012 NSG 7430 - Pharmacology for Advanced Practice Nurses

Pain Management (3 contact hours annually)

Adjuvant Treatments in Cancer (3 contact hours annually)


Spring 2004 Integrated Applied Therapeutics II (PHR 963)

(2 contact hours)

Fall 2004 Integrated Applied Therapeutics I (PHR 962)

(2 contact hours)

Fall 2003 Contemporary Aspects of Pharmacy Practice (PHR 939)

(8 contact hours)

Spring 2002 Contemporary Aspects of Pharmacy Practice (PHR 919)

(8 contact hours)

University of Kentucky College of Allied Health Sciences-Physician Assistant

Spring 2003 Pharmacology Course

Immunomodulating Agents

Antineoplastic Agents

(2 contact hours)

POSTGRADUATE TRAINEES


7

PGY2 Oncology Pharmacy Residency Program Director

Year Graduate Resident First Clinical Position

2011-2012 Katerina Katsanevas Butler, Pharm.D BCOP

Oncology Clinical Specialist VA Medical Center Salt Lake City, UT

2012-2013 Stephen Clark, Pharm.D. BCOP BMT Clinical Specialist University of North Carolina

Chapel Hill, NC

2012-2013 Alison Steinbach, Pharm.D Outpatient Clinical Specialist West Penn Allegheny Hospital

Pittsburgh, PA

2013-2014 Megan Hartranft, Pharm.D. BCPS, BCOP

Clinical Assistant Professor Rosalind Franklin College of Pharmacy

Rush Cancer Center Chicago, IL

2014-2015 Sarah Evans, Pharm.D. BCOP Outpatient Clinical Specialist The Ohio State Medical Center

James Cancer Center Columbus, OH

2015- 2016 Julianne Orr, Pharm.D. Outpatient Clinical Specialist Indiana Health Indianapolis, IN

2016-2017 Ben Andrick, Pharm.D. BMT Clinical Specialist Geisinger Health System

Danville, PA

7/2017-8/2017 Morgan Gwynn, Pharm.D. PGY2 Resident at AU/UGA

UGA Clinical and Experimental Therapeutics (CET) Clinical Program Training

Year Graduate Student Rotation

2010 Belal Al-Husein, M.S. Inpatient Oncology

2012 Ahmed Al-Azayzih, Pharm.D. BCOP Inpatient Oncology

2014 Harika Sabbineni, B.Pharm. Outpatient BMT

UGA Clinical and Experimental Therapeutics Dissertation Committee Member

Year Graduate Student Thesis Title

2010-2011 Belal Al-Husein, M.S. Molecular mechanisms regulating simvastatin-mediated inhibition of prostate cancer cellular functions in vitro and tumor growth in vivo


8

2011-2012 Ahmed Al-Azayzih, Pharm.D. BCOP Role of Akt in myofibroblast differentiation leading to pulmonary vascular remodeling and idiopathic pulmonary fibrosis

2015-current Abdul M. Alwhaibi, Pharm.D. In-progress

PGY1 Pharmacy Residency Precepting

Year Graduate Resident Rotation

2010-2011 Katerina Katsanevas, Pharm.D BCOP

Inpatient hematology/oncology

2009-2010 Karly O’Brien, Pharm.D. Inpatient hematology/oncology

2009-2010 Ashley Richard, Pharm.D. Inpatient hematology/oncology

2009-2010 Amber Bradley, Pharm.D. BCOP Inpatient hematology/oncology

2008-2009 Neha Dosi, Pharm.D. Inpatient hematology/oncology

2008-2009 Evelina Maciuleviciute, Pharm.D.

Inpatient hematology/oncology

2007-2008 Tim Robinson, Pharm.D. BCPS Inpatient hematology/oncology

2007-2008 Kinjal Vikal, Pharm.D. Inpatient hematology/oncology

CERTIFICATIONS/OTHER TRAINING

2015 Chairs and Academic Administrators Management Program (CAAMP)

Academy for Academic Leadership

Atlanta, GA

2014 ACCP Focused Investigator Training (FIT) Program

Athens, GA

2012 CITI- Collaborative IRB Training Initiative Certification

Georgia Health Sciences University

Refresher Course Completed (2006, 2009)

2012 CITI Certification for Institutional Review Board Members

Georgia Health Sciences University

2007 Biosafety Training Certification


9


2006 Saf-T-Pak Inc Biological Specimens Certification

Recertification (2015- Safe Transports of Biological Substances)


2004 Scholarship of Teaching and Learning Certificate Program


2003 Navigating the Clinical Research Process Investigator Training


2003 Advanced Cardiac Life Support Certification


2002 Adult Immunizations Certification


PRESENTATIONS

National

1. Schedule-dependent Synergism and Antagonism between Paclitaxel and Topotecan in Human

Ovarian Cancer Cell Lines in vitro. Scientific Paper Platform Presentation. Presented at American

College of Clinical Pharmacy (ACCP) Annual Meeting; San Francisco, CA. October 2005

2. Strategies for Success in Pharmacy Board Certification: A Panel Discussion. Panel – Smith KM,

Canada TW, Divine H, Jennings HR. Presented at the 42nd American Society of Health Systems

Pharmacists (ASHP) Midyear Clinical Meeting; Las Vegas, NV. December 2, 2007

3. Hodgkin Lymphoma BCOP Recertification Presentation. Presented at the 9th Annual Hematology

Oncology Pharmacists Association (HOPA) Annual Meeting; Los Angeles, CA. March 2013.

4. Trending now #ExcellenceInPrecepting – effective ways to incorporate social media into clinical

practice. Co-presenters- Clark S and Hartranft M. Presented at the ASHP National Pharmacy

Preceptors Conference; Washington DC. August 22, 2013.

5. Have you submitted that paper yet? Successfully precepting student and resident research

projects. Co-presenters- May JR, Phillips BJ, Phillips M. Presented at the ASHP National

Pharmacy Preceptors Conference; Washington DC. August 23, 2013.

6. Hodgkin Lymphoma BCOP Recertification Presentation. Presented at American College of

Clinical Pharmacy (ACCP) Annual Meeting Albuquerque, NM. October 15, 2013.


10

7. Hodgkin Lymphoma BCOP Recertification Presentation. Presented at ASHP Annual Meeting

Orlando, FL. December 10, 2013.

8. Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients:

Correlation with clinical outcomes and drug response. The Great Eight Best Paper Presentations

Series. Presented at American College of Clinical Pharmacy (ACCP) Annual Meeting Austin, TX.

October 13, 2014

9. Hematology/Oncology PRN Focus Session: Confronting the Global Epidemic of Human

Papillomavirus (HPV) and Associated Malignancies. Moderator at Global American College of

Clinical Pharmacy (ACCP) Annual Meeting San Francisco, CA. October 19, 2015.

10. Recent Advances in the Treatment and Management of Lymphomas. Presented at HOPA BCOP

Updates Course Orlando, FL. July 16, 2016.

11. Malignancy in the HIV Patient. Presented at the ACCP Annual Meeting Hollywood, FL. October

24, 2016.

12. Oral Chemotherapy Education. Presented at the National Community Oncology Dispensing

Association (NCODA) Annual Summit Atlanta, GA. October 29, 2016.

13. Managing Acute Lymphoblastic Leukemia (ALL): A Review on Diagnosis and Clinical

Considerations for the Healthcare Professional. Webinar provided by Specialty Pharma

Education Center, 2016.

14. Cracking the Code on Oral Chemotherapy: Pharmacotherapy Management and Counseling

Strategies. Presented at the ACCP Annual Meeting Phoenix, AZ. October 10th, 2017.

15. Oral Chemotherapy Education. Presented at the NCODA Annual Meeting Orlando, FL. October

19, 2017.

16. Emerging Treatment Options for Relapsed/Refractory Hodgkin Lymphoma. ASHP Advantage

Webinar. October 26, 2017.

Regional

1. The Specific Role of 92kDa Type IV Collagenase in Metastatic Tumor Cells Howard Hughes

Research Award Winners Presentation. Kentucky/Tennessee Academy of Science Joint Meeting

Bowling Green, KY. May 1996


11

2. Erythropoietin Response in Patients Concurrently Receiving Capecitabine ACPE accredited

continuing education program. Southeastern Residency Conference University of Georgia.

Athens, GA. May 2003

3. Thymoquinone: Analytical Method and Assay Validation. Southeastern Residency Conference.

ACPE accredited continuing education program. University of Georgia. Athens, GA. May 2004

4. Selected Overview of Recently Approved Oncology Agents: Targeting New Molecular Targets

Kentucky Health System Pharmacists (KSHP) Annual Meeting. ACPE accredited continuing

education program.. Lexington, KY. September 2004.

5. New Oncology Agents. Georgia Health System Pharmacists (GHSP) Fall Annual Meeting

ACPE accredited continuing education program. Helen, GA October 2006.

6. The Generational Joust: Strategies for Boomers and GenXers as the Millennials Enter the

Profession of Pharmacy. Georgia Health System Pharmacists (GHSP) Summer Annual Meeting.

ACPE accredited continuing education program. Amelia Island, FL June 2008

7. Breast and Gynecological Cancers. South Carolina Pharmacists Association Summer Meeting

ACPE accredited continuing education program. Hilton Head, SC June 2010.

8. Managing Vascular Complications Associated with Novel Targeted Chemotherapy Agents

Georgia Health System Pharmacists (GHSP) Summer Annual Meeting. ACPE accredited

continuing education program. Amelia Island, FL July 2012.

9. Confronting the Rise of Cancers in the HIV Population. Georgia Health System Pharmacists

(GHSP) Summer Annual Meeting. ACPE accredited continuing education program. Amelia Island,

FL July 2017.

State

1. Angiogenesis: Switching On/Off Molecular Targets for Differing Clinical Outcomes ACPE

accredited continuing education program. MCG/UGA Pharmacy Grand Rounds, Augusta, GA.

February 2006.

2. What’s “Hot” in the Treatment of Leukemias. ACPE accredited continuing education program

MCG/UGA Pharmacy Grand Rounds, Augusta, GA. October 2006.

3. Perspective of a New Generation Xer Professor- Challenges and Strategies of Teaching the

Millennials. ACPE accredited continuing education program/ MCG/UGA Pharmacy Grand

Rounds, Augusta, GA. October 2007.

4. Neurotoxicity of Chemotherapeutic Agents. MCG Neurology Resident Ground Rounds Series


12

Medical College of Georgia, Augusta, GA. February 2008.

5. Recent Significant Advances in Oncology. ACPE accredited continuing education program.

MCG/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to Savannah and Athens,

GA. April 2009.

6. Making it less MUDdy: Understanding Matched Unrelated Donor Bone Marrow Transplants.

ACPE accredited continuing education program. GHSU/UGA Pharmacy Grand Rounds, Augusta,

GA. Transmitted video to Savannah, Athens, and Albany, GA. April 2011

7. Maintaining the Maintenance: Is this the Future of Cancer Therapy. ACPE accredited continuing

education program. GHSU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted video to

Savannah, Athens, and Albany, GA. October 2012.

8. Recent Advances in Cancer Immunotherapy: Developing a Killer Instinct. ACPE accredited

continuing education program. GRU/UGA Pharmacy Grand Rounds, Augusta, GA. Transmitted

video to Savannah, Athens, and Albany, GA. September 2014.

9. Hematopoietic Growth Factors. Augusta University Division of Hematology/Oncology Fellows

Grand Rounds. February 8, 2017.

PEER-REVIEWED PUBLICATIONS

1. Sisken J, DeRemer DL. Power frequency electromagnetic fields and the capacitative calcium

entry system in SV40-transformed Swiss 3T3 cells. Radiation Research 2000;153:699.

2. Ustun C, Farrow S, El-Geneidy, DeRemer D, Jillella A. A serious complication of allogeneic

stem cell transplantation: Relapsing Pseudomonas aeruginosa panniculitis. Clinical Medicine:

Oncology 2007: I 91-94

3. Ustun C, Farrow S, DeRemer D, Fain H, Jillella A. Early fatal Rhizopus infection on voriconazole

prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2007 Jun;

39(12):807-8.

4. Ustun C, DeRemer DL, Steele J, Forseen C, Fisher JF, Jillella AP. Fatal breakthrough

Aspergillus fumigatus and Candida glabrata infections in a leukemia patient on

posaconazole prophylaxis. Int J Antimicrob Agents. 2008 Oct; 32(4):365-6.

5. Ustun C, Kalla A, Farrow S, DeRemer DL, Jillella A. Decitabine as “bridge therapy” to

a MUD transplant in relapsed AML postautologous stem cell transplantation.

Am J Hematol. 2008 Oct; 83(10):825-7


13

6. DeRemer DL, Natarajan K, Ustun C. Nilotinib (Tasigna®): A second generation tyrosine

kinase inhibitor for the treatment of chronic myelogenous leukemia.

Clin Ther. 2008 Nov;30(11):1956-75.

7. Ustun C, DeRemer DL, Jillella A, Bhalla KN. Investigational drugs targeting FLT3 for leukemia.

Expert Opinion Investig Drugs 2009 Oct;18(10):1445-56.

8. Adams VR, DeRemer DL, Stevich B, Mattingly C, Gallt B, Subramanian T, Troutman HM,

Speilmann HP. Anticancer activity of novel unnatural synthetic isoprenoids. Anticancer Res.

2010 Jul;30(7):2505-12.

9. Lewis G, Hall P, Eisa N, DeRemer DL, Dobbins R, El-Geneidy M, Jillella A, Ustun C. Acute

myelogenous leukemia patients are at low risk for invasive fungal infections after high dose

cytarabine consolidations and thus do not require prophylaxis. Acta Haematologica 2010

Nov 12;124(4):206-213

10. Ustun C, Jillella A, Shah R, Sterling K, DeRemer DL, et al. Second allogeneic stem cell

transplantation from different donor improves severe steroid-resistant gut GVHD.

Bone Marrow Transplant 2010 Nov;45(11):1658-60

11. Willis LM, Somanath PR, El-Remessy AB, DeRemer DL, Fagan SC.

Angiotensin receptor blockers and angiogenesis: Clinical and experimental evidence.

Clin Science 2011 Apr; 120 (8):307-19

12. DeRemer DL, Katsanevas K, Ustun C. Critical appraisal of nilotinib in the front-line treatment of

chronic myeloid leukemia. Cancer Manag and Res. 2011 Mar 10:3:65-78.

13. Ustun C, DeRemer DL, Akin C. Tyrosine inhibitors in the treatment of systemic mastocytosis.

Leukemia Res. 2011 Sep;35(9):1143-52

14. Hammadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K,

Morrison, D, Speir E, DeRemer D, Kota V, Jillella A, Craig M, Awan F. Intermediate –versus low

dose cyclophosphamide and granulocyte colony stimulating factor for peripheral blood stem cell

mobilization in multiple myeloma patients treated with novel induction therapies. Biol Blood

Marrow Transplant. 2012 Jul;18(7):1128-35

15. Awan F, Kochuparambil ST, DeRemer D, et al. Plerixafor salvage is safe and effective in

hard-to-mobilize patients undergoing chemotherapy and filgrastim-based peripheral blood

progenitor cell mobilization. J Oncol 2012;2012: 931071

16. Al-Husein B, Abdalla M, Trepte M, DeRemer DL, Somanath PR. Anti-angiogenic therapy for

cancer: An update. Pharmacotherapy. 2012 Dec;32(12):1095-111.


14

17. DeRemer DL, Katsanevas K, Bradley A, Awan F. Romiplostim resistance in secondary failure of

platelet recovery (SFPR). J Oncol Pharm Pract 2013 Dec;19(4):369-72

18. Bradley A, Devine M, DeRemer DL. Brentuximab vedotin: A novel antibody-drug conjugate. Am

J Health Syst Pharm. 2013 Apr 1;70(7):589-97

19. Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, DeRemer D, Jillella

A, Craig M, Hamadani M. Comparable efficacy and lower cost of PBSC mobilization with

intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients

with multiple myeloma treated with novel therapies. Bone Marrow Transplant 2013

Oct;48(10):1279-84

20. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL, Somanath PR.

Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells

inhibit prostate cancer progression in vitro and in vivo. Oncotarget 2014 15;5(3):775-87.

21. Bradley A, Evans S, DeRemer DL, Awan F. Busulfan dosing (Q6 or Q24) with adjusted or actual

body weight, does it matter? J Oncol Pharm Pract. 2015 Dec;21(6):425-32.

22. Clark SM, Clemmons A, Schaack L, Garren J, DeRemer DL, Vota V. Fosaprepitant for the

prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before

autologous hematopoietic stem cell transplant. J Oncol Pharm Pract. 2016 Jun;22(3):416-22.

23. Hartranft M, Clemmons A, DeRemer DL, Kota V. Evaluation of romiplostim for the treatment of

secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant

patients. J Oncol Pharm Pract. J Oncol Pharm Pract. 2017 Jan;23(1):10-17

24. DeRemer DL, Clemmons AB, Orr J, Clark SM, Gandhi A. Emerging role of olanzapine for

prevention and treatment of chemotherapy-induced nausea and vomiting. Pharmacotherapy.

2016 Feb;36(2):218-29.

25. Mangonkar A, Xu H, Moshin J, Mansour J, Chintalapally R, Keen R, Mondal AK, DeRemer D, et al.

Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia.

J Community Support Oncol. 2016 Feb;14(2):66-71.

26. Evans SS, Gandhi AS, Clemmons AB, DeRemer DL. Clinical and cost comparison evaluation of

inpatient versus outpatient administration of EPOCH‐Containing regimens in Non‐Hodgkin

lymphoma. J Pharm Pract. 2016 Jul 18. pii: 0897190016659210. [Epub ahead of print]

27. Deal EN, Stranges PM, Maxwell WD, Bacci J, Ashjian EJ, DeRemer DL, et al. The importance of

research and scholarly activity in pharmacy training. Pharmacotherapy. 2016 Dec;36(12):e200-

e205.


15

28. Andrick B, Alwahibi A, DeRemer DL, Quershi S, Khan R, Bryan L, Somanath PR, Pantin J. Lack of

adequate pneumococcal vaccination response in chronic lymphocytic leukemia patients

receiving ibrutinib. Br J Haematol. 2017 Jul 24 [epub ahead of print]

29. Gwynn ME, DeRemer DL. The emerging role of PD-1/PD-L1 targeting immunotherapy in the

treatment of metastatic urothelial carcinoma. Ann Pharmacother. 2017 Aug 1 [epub ahead of

print]

NON-PEERED REVIEWED

1. Adams VR, DeRemer, DL, Kilbridge JF. Apoptosis: Novel Molecular Targets in

Cancer Therapy, Clinical Focus on Bcl-2. Oncology Special Edition Dec 2004.

2. DeRemer DL. Blincyto® (blinatumomab) for patients with Philadelphia chromosome-negative

relapsed or refractory B-Cell precursor acute lymphoblastic leukemia. Submitted to Pharmacy

Practice News March 2015.

3. DeRemer DL. Empowering Community Pharmacists as Health Consultants: Chemotherapy-

Induced Nausea and Vomiting. Inside Patient Care. December 2015.

BOOK CHAPTERS

1. Gerson SL, Bhalla KN, Grant S, Natarajan K, Grant S, Creger RJ, DeRemer D. Pharmacology and

Molecular Mechanisms of Antineoplastics Agents for Hematologic Malignancies. In:

Hematology: Basic Principles and Practice (eds Hoffman R, Silberstein LE, Shattil SJ, et al.) 5th

edition. Elsevier, Philadelphia, PA. 2008, p 839-873.

2. DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 1st edition. McGraw-Hill., New York.

2011 p143 -150.

3. DeRemer DL, Manasco KB, Fagan SC. Research: Becoming a Scholar. In: Murphy JE (ed)

American College of Clinical Pharmacy Resident Survival Guide. Lenexa, KS, 2011.

4. DeRemer DL. Drug and Food Interactions with Tyrosine Kinase Inhibitors. In: Ustun C and Popat

UR (eds): Chronic Myeloid Leukemia: From Daily Management to Complicated Issues. New York,

NY: Nova Science Publishers; 2014 pp. 251-262.

5. DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 2nd edition. McGraw-Hill., New York.

2015.

6. DeRemer DL Leukemias. In: Sutton NAPLEX Review Guide. 3rd edition. McGraw-Hill., New York.

2017. (Submitted)


16

HANDBOOKS

1. Adams, V.R., DeRemer, DL, Holdsworth, MT. Guide to Cancer Chemotherapeutic Regimens.

McMahon Publishing, New York, NY 2004



















11. Adams, V.R. DeRemer DL, Bernhardt, MB. Guide to Cancer Therapeutic Regimens. McMahon

Publishing, New York, NY 2017.

ABSTRACTS/POSTERS

1. Liewer SE, Hecht KA, Smith, CA, DeRemer DL, Adams VR, et al. Gelclair® for the treatment

chemotherapy induced stomatitis in transplant and hematology patients: An interim analysis.

Blood. 2004 Nov 16;104: 5317


17

2. Gallt RR, Mattingly CA, DeRemer DL, Adams VR. Determination of in vitro growth inhibition by

novel farnesyl diphosphate analogues. American College of Clinical Pharmacy (ACCP) Annual

Meeting 2005 San Francisco, CA. Abstract #511

3. DeRemer DL, Mattingly CA, Adams VR. In vitro interaction between topotecan (TPT) and

paclitaxel (PAC) in three human ovarian cancer cell lines. ACCP Annual Meeting 2005 San

Francisco, CA. Abstract #245

4. Kendrick A, Lake B, DeRemer D, Fain H, Farrow S, Ustun C, and Jillella A. Analysis of febrile

neutropenia in multiple myeloma patients post-autologous hematopoietic stem cell

transplantation (HSCT). Presented at the 2007 American Colleges of Clinical Pharmacy Annual

Meeting Denver, CO; October 15, 2007. Abstract #353.

5. Kendrick A, DeRemer DL. Evaluation of institutional BMT program compliance with

recommended post-hematopoietic stem cell transplant (HSCT) vaccination guidelines.

Presented at 2007 American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV;

December 2007

6. Fussell J, Boyle K, Kuth J, DeRemer DL, Ustun C. Review of institutional use of prophylactic

voriconazole and posaconazole in patients with hematological malignancies. Presented at 2007

American Health System Pharmacy (ASHP) Annual Meeting Las Vegas, NV; December 2007.

7. Stevich B, Mattingly C, DeRemer DL, Spielmann P, Adams V. Targeting Ras with false prenyl

analogs. Presented at 2008 American Colleges of Clinical Pharmacy (ACCP) Annual Meeting

Louisville, KY; October 2008.

8. Carbonell C, DeRemer DL. Institutional analysis of rasburicase in the management of tumor lysis

syndrome. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting

Orlando, FL. December 2008.

9. Nestor MA, DeRemer DL. Evaluation of outcomes in acute promyelocytic leukemia patients

receiving ATRA (All-trans Retinoic Acid). Presented at 2008 American Health System Pharmacy

(ASHP) Annual Meeting Orlando, FL. December 2008

10. Almeter PJ, Robinson T, DeRemer DL. Institutional evaluation of vancomycin in neutropenic

patients. Presented at 2008 American Health System Pharmacy (ASHP) Annual Meeting Orlando,

FL. December 2008.

11. Maciuleviciute E, Davis W, DeRemer DL. Evaluation of hypertension management bevacizumab

treated patients. Presented at the 2008 University Health Consortium Pharmacy Council

Resident Poster Session, Orlando, FL. December 6, 2008


18

12. Graham CR, Butterfield J, DeRemer DL. Impact of peptide nucleic acid fluorescence in situ

hybridization (PNA FISH)-based identification of Candida species on antifungal utilization.

Presented at the 2009 University Health Consortium Pharmacy Council Resident Poster Session,

Las Vegas, NV. December 5, 2009

13. Mebel E, McAllister J, DeRemer DL. Evaluation of plerixafor on stem cell collection prior to an

autologous hematopoietic stem cell transplant (aHSCT). Presented at 2009 American Health

System Pharmacy (ASHP) Annual Meeting Las Vegas, NV. December 2009.

14. Awan F, DeRemer D, Mebel E, et al. Utility of plerixafor in addition to chemotherapy and G-CSF

mobilization regimens. Blood (American Society of Hematology (ASH) Annual Meeting)

2010;116: 4443.

15. Katsanevas K, Ajiboye V, DeRemer DL. Evaluation of pegfilgrastim for primary prophylaxis for of

neutropenic fever. Presented at the 2010 University Health Consortium Pharmacy Council

Resident Poster Session, Anaheim, CA. December 4, 2010

16. Kochuparambil T, DeRemer DL, Mebel ER, Jillella AP, Awan F. Optimizing the efficacy of

plerixafor as a salvage option in poor mobilizers following chemotherapy plus G-CSF. Presented

at the 2011 American Society for Blood and Marrow Transplantation (ASBMT) Meeting.

Honolulu, HI. February 17-21, 2011

17. Stoudenmire LL, Trepte M, McCracken C, Katsanevas K, DeRemer DL. Evaluation of obesity on

achieving remission following induction therapy for acute myelogenous leukemia. ACCP Annual

Meeting 2011 Pittsburgh, PA. Abstract # 448

18. Morrison DD, Kochuparambil ST, DeRemer DL, et al. Clinical Practice Guideline for the treatment

of BK-Virus induced Hemorrhagic Cystitis in the Post-Allogeneic Hematopoietic Stem Cell

Transplant Setting. Volume 18 Issue 2. Presented at the American Society of Bone Marrow

Transplant (ASBMT) Annual Meeting at San Diego, CA. Feb 1-5, 2012.

19. Hamadani S, Kochuparambil ST, Osman S, Speir E, Craig M, DeRemer D, et al. Intermediate-

versus low-dose cyclophosphamide and granulocyte colony stimulating factor for peripheral

blood progenitor cell mobilization in patients with multiple myeloma treated with novel

induction chemotherapies – A multicenter analysis. Blood (ASH Annual Meeting Abstracts), Nov

2011;118: 313.

20. Katsanevas K, Al-Husein B, DeRemer D, Shenoy S. Is GSK-3 the gridlock in Akt-targeted prostate

cancer therapy? Presented at the 2012 Hematology/Oncology Pharmacist Association (HOPA)

Meeting, Orlando, FL. March 22, 2012.


19

21. DeRemer DL, Katsanevas K, Forehand C, et al. Successfully integrating translational research

into a PGY2 research project. Presented at the 2012 ASHP National Residency Preceptors

Conference in Washington, DC. August 17, 2012.

22. DeRemer DL, Katsanevas K, Lou U, et al. Src inhibition with dasatinib offers potential benefit for

prostate cancer. Presented at the 2012 STAR (Southern Translational Research) Conference in

Augusta, GA. September 6, 2012.

23. Evans S, DeRemer D, Bradley A. Intravenous busulfan pharmacokinetics in conditioning

regimens for allogeneic stem cell transplantation: impact of dosing weight on clinical outcomes.

Presented at the 2012 STAR (Southern Translational Research) Conference in Augusta, GA.

September 6, 2012.

24. Awan F, Kochuparambil ST, Craig M, Cumpstom A, Leadmon, S, Watkins K, DeRemer D, Pantin J,

Kota V, Jillella AP, Hamadani. Intermediate-Dose Cyclophosphamide Versus Plerixafor and

Granulocyte Colony Stimulating Factor (G-CSF) for Peripheral Blood Progenitor Cell (PBPC)

Mobilization in Patients with Multiple Myeloma (MM) Treated with Novel Induction

Chemotherapies – A Multicenter Analysis. Blood (ASH Annual Meeting Abstracts), Nov 2012;

120: 4409

25. Steinbach A, Goc A, DeRemer D, Shenoy S. Evaluation of cabazitaxel and dasatinib on the

reciprocity between prostate cancer and the endothelium in the prevention of micrometastasis.

Presented at the 9th Annual HOPA Conference in Los Angeles, GA. March 21, 2013.

26. Schaack L, Clark SM, Clemmons AB, DeRemer DL, Kota V. Characterization of chemotherapy

induced nausea and vomiting outcomes in patients receiving melphalan-containing conditioning

chemotherapy for autologous hematopoietic stem cell transplant. Presented at 2013 ACCP

Annual Meeting in Albuquerque, NM. Abs #347

27. Clark SM, Schaack L, DeRemer D, Kota V, Clemmons AB. Fosaprepitant for the prevention of

nausea and vomiting in patients receiving BEAM or high-dose melphalan conditioning regimens

for autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014

Feb;20(2 Suppl):S287.

28. Hartranft ME, DeRemer DL, Kolhe R, Phillips BG. Investigation of epigenetic modifications in

obese and non-obese acute myeloid leukemia patients. Presented at 10th Annual Meeting of the

Hematology/Oncology Pharmacy Association (HOPA), New Orleans, LA. Resident Trainee Poster

#125

29. DeRemer DL, Hartranft ME, Mondal A, Kolhe R, Meagher R, Phillips BG. Evaluation of the effects

of obesity on the epigenome in acute myeloid leukemia patients: Correlation with clinical

outcome and drug response. Presented at 2014 ACCP Annual Meeting in Austin, TX. Abs#442.


20

30. Evans S, Clemmons AB, Gandhi A, DeRemer D. Clinical and economic evaluation of inpatient

versus outpatient administration of EPOCH-containing regimens in Non-Hodgkin lymphoma.

Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy Association (HOPA),

Austin, TX. Resident Trainee Poster #32

31. Orr J, Clemmons AB, Gandhi A, DeRemer D. Randomized, placebo-controlled study of FOND

(fosaprepitant, ondansetron, dexamethasone) versus FOND+O (FOND plus olanzapine) for the

prevention of CINV in hematology patients receiving highly emetogenic chemotherapy regimens

(The FOND-O Study). Presented at 12th Annual Meeting of the Hematology/Oncology Pharmacy

Association (HOPA), Atlanta, GA. Resident Trainee Poster #100

32. Andrick B, DeRemer D, Abdul Sater- H, Bollag R, Pantin J, Shenoy S. Pneumococcal vaccine

response in chronic lymphocytic leukemia patients with ibrutinib. Presented at 12th Annual

Meeting of the Hematology/Oncology Pharmacy Association (HOPA), Atlanta, GA. Resident

Trainee Poster #27

33. Andrick B, Alwhaibi A, DeRemer D, Quershi, Khan R, Shenoy S, Pantin J. Antibody response to

pneumococcal conjugate vaccine (PCV13) in chronic lymphocytic leukemia patients receiving

ibrutinib. Blood 2016 128:5597.

34. George TJ, Starr JS, Parkeh HD, Ivery AM, Dang LH, Daily KC, Allegra CJ, DeRemer DL, et al. Final

toxicity results from a phase II study of 5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) in

previously untreated metastatic pancreatic adenocarcinoma. Submitted to 2018 GU ASCO

Meeting.

GRANTS

1. Analysis of febrile neutropenia in multiple myeloma patients post-autologous hematopoietic

stem cell transplantation. University of Georgia Randy Ellison Cancer Research Grant. Project

period 10/06-5/07. (Primary Investigator, 50% effort). Total award $2000

2. Is GSK-3 the gridlock in Akt-targeted prostate cancer therapy? University of Georgia

Translational Research Initiative Grant. Project period 10/11-07/12. (Sub-Investigator, 5%

effort). Total award $7500

3. Evaluation of cabazitaxel and dasatinib on the reciprocity between prostate cancer and the

endothelium in the prevention of micrometastasis. Submitted 9/12 for University of Georgia

Translational Research Initiative Grant. Project period 10/12-07/13. (PI, 5% effort). Total award

$10,000

4. Examining TGFβ and Integrin αvβ3 Expression in Early and Aggressive Human Prostate and

Bladder Cancer Tissues as Biomarkers for early detection and as targets for therapy. Project


21

period 2013-14. University of Georgia Translational Research Initiative Grant. (Sub-investigator,

5% effort). Total award $10,000

5. Evaluation of the effects of obesity on the epigenome in acute myeloid leukemia patients:

Correlation with clinical outcome and drug response. University of Georgia College of Pharmacy

R.C. Wilson Fund. Project period 2014-2015. (PI, 75% effort). Total award $4,500

6. Pneumococcal vaccine response in chronic lymphocytic leukemia (CLL) patients receiving

ibrutinib. University of Georgia College of Pharmacy R.C. Wilson Fund. Project period 2015-

2016. (PI, 75% effort). Total award $4,000

CLINICAL TRIALS

1. A Phase IA/II, two-arm, multi-center, open-label, dose escalation study of LBH589 administered

orally via different dosing schedules in adult patients with advanced hematological

malignancies. – Role: Institutional Sub-I. 2006-2008.

2. A Phase I dose finding study of the anti-angiogenesis agent, AG-013736 in combinations of

paclitaxel/carboplatin, weekly paclitaxel, docetaxel, capecitabine, and gemcitabine/cisplatin in

patients with advanced solid tumors. - Role: Institutional Sub-I. 2007.

3. Randomized, placebo-controlled study of FOND (fosaprepitant, ondansetron, dexamethasone)

versus FOND+O (FOND plus olanzapine) for the prevention of chemotherapy induced nausea

and vomiting in hematology patients receiving highly emetogenic chemotherapy regimens: the

FOND-O Study. (NCT02635984)- Investigator Initiated Trial, Role: Institutional Sub-I. 2015-

current

4. An open-label study of rovalpituzumab tesirine in subjects with delta-like protein 3-expressing

advanced solid tumors. Role: Institutional Sub-I. 2017-current

5. A Phase I, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102

in patients with advanced solid tumors and varying degrees of renal impairment. Role:

Institutional Sub-I. 2017-current

6. A Phase 1/2, Open-label study of nivolumab monotherapy or nivolumab combined with

ipilimumab in subjects with advanced or metastatic solid tumors. Role: Institutional Sub-I. 2017-

current

7. A Phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the

safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447

alone and in combination with MEDI4736 in adult subjects with select advanced solid tumors.

Role: Institutional Sub-I. 2017-current


22

8. A Phase 1/2 study exploring the safety, tolerability, and efficacy of INCAGN01876 in combination

with immune therapies in subjects with advanced or metastatic malignancies. Role: Institutional

Sub-I. 2017 –current

OTHER SCHOLARLY/CREATIVE WORKS

1. In collaboration, developed – Required competency areas, goals, and objective for PGY2

Oncology Pharmacy Residencies (2017) - http://www.ashp.org/DocLibrary/Residents/Oncology-

Pharmacy-2016.pdf

HONORS AND AWARDS

2015 Elected to Fellowship in ACCP

2014 ACCP Annual Meeting – Best Paper Award

2014 ACCP Hematology/Oncology PRN FIT Program Scholarship Recipient

2012 Georgia Society of Health-System Pharmacists (GHSP) Outstanding

Practitioner of the Year

2005 ACCP Research Travel Award

2003 Clinical Pharmacy Residents Program Educational Grant- Pfizer

2003 University of Kentucky Medical Center Resident of the Month

1996 Howard Hughes Research Institute Research Award

ADMINISTRATIVE ACTIVITY/COMMITTEES

University of Florida Health Cancer Center

2017-present Member, Scientific Review and Monitoring Committee

2017-present Member, Data Integrity and Safety Committee


2016-2017 Academic and Professionalism Committee

2013-2017 Student Wellness Committee

2013-2017 Students Oncological Advocates in Pharmacy (SOAP)- Faculty Advisor

http://www.ashp.org/DocLibrary/Residents/Oncology-Pharmacy-2016.pdf

http://www.ashp.org/DocLibrary/Residents/Oncology-Pharmacy-2016.pdf


23

2014-2016 Academic House Host – Augusta PGY3 students

2014-2016 Chair, Clinical Tracks Work Group

2010- 2012 UGA Faculty alternative delegate for American Association of Colleges

of Pharmacy (AACP)

2009-2013 Member, Scholarship and Awards Committee

2012-2013 Chair

2007-2009 Member, Faculty Development Committee

2006-2009 Admissions Committee

Augusta University (formerly known as -Georgia Regents University (GRU)

2012-2017 Member, Cancer Institutional Review Board (C-IRB)

2012-2017 Associate Member GRU Cancer Center

2008-2017 GRU/UGA Pharmacy Residency Advisory Committee (RAC) member

2006-2017 GRU BMT/Hematologic Malignancies Committee

2005-2017 GRU Oncology Pharmacy and Therapeutics Subcommittee

2005-2006 Medical College of Georgia (now GHSU) Palliative Care Committee

University of Kentucky

2003-2005 UK Oncology Pharmacy and Therapeutics Subcommittee

2003-2004 UK Medical Center Medication Use Evaluation Subcommittee

2002-2003 UK College of Pharmacy Admissions Committee (Resident member)

PROFESSIONAL ACTIVITY

2017- present American Society of Clinical Oncology (ASCO) member

2015-present National Community Oncology Dispensing Association (NCODA)

o Executive Advisory Board

2006-present Georgia Health Systems Pharmacy (GSHP) member

2006-present Hematology/Oncology Pharmacy Association (HOPA) member

o Vice-Chair, Tools and Resources Committee (2017)

o Board of Directors, Member at Large (2015- 2017)

Advocacy HOPA On the Hill Day Washington, DC 2015,

2016, 2017

Committee Restructuring Task Force 2016

Board Liaison, Practice Management (2016-2017)

Board Liaison, Annual Program Committee (2016-2017)

Board Liaison, Membership Committee (2015-2016)

Board Liaison, Publications Committee (2015- 2016)

BIG idea Taskforce (2015-current)


24

o Recognition Committee, Vice Chair (2014- current)

o Research and Abstract Review Committee (2010-2013)

o Poster Reviewer (2009-2012)

2002-present American College of Clinical Pharmacy (ACCP) Associate member

o Research Committee, member (2015-2016)

o Hematology/Oncology PRN Chair (2015-2016)

o Hematology/Oncology PRN Chair Elect (2014-2015)

o Hematology/Oncology PRN program committee (2014-current)

o Academy Resident Mentor participant (2013- current)

Mentee – Julianne Orr, Pharm.D. (PGY1 Resident,

Greenville Health System)

Mentee- Sarah Hayes, Pharm.D. (PGY1 Resident, N.

Memorial Medical Center)

Mentee- Deeter Neuman, Pharm.D. (PGY1 Resident,

University of Michigan)

Mentee – Manuel Cortez, Pharm.D. (PGY2 Oncology

Resident, University of Chicago)

o Student CV Reviewer (2012- current)

o Student Trivia Game Writer – Oncology (2010-2011) and (2016-

2017)

o Hematology/Oncology PRN Member (2003- current)

2012-2014 American Society for Blood and Marrow Transplantation – Affiliate

member

2005-2007 ASCO member

2002-2005 Kentucky Health System Pharmacists (KSHP) member

2001-present American Society of Health System Pharmacists (ASHP)

1998-2002 Kappa Psi Pharmaceutical Fraternity

CONSULTING

2013-2016 Merck – Speakers bureau

2010-2012 Georgia Department of Public Health - Georgia Cancer State Aid

Program Formulary Reviewer

SCIENTIFIC JOURNAL REFEREE AND BOOK REVIEWER

Books

Pharmacotherapy Principles and Practice -3rd edition

Chapter- Malignant Lymphomas


25

Journals

2017-present Supportive Care in Cancer

2017-present Journal of Pharmacy Technology

2016-present BMJ Open

2014-present Journal of Hematology/Oncology Pharmacy

2013-present Annals of Pharmacotherapy

2013-present Pharmacotherapy

2012-present American Journal of Health Systems Pharmacists

EDITORIAL ACTIVITY

Computer Apps for Oncology Professionals

2014- 2016 Essential oncology/McMahon Publishing

COMMUNITY SERVICE

2013-2017 Upward Sports Coach (Soccer, Basketball)

2009-2017 Leukemia and Lymphoma Society – Light the Night fundraising GRU

team member

2003-2005 Life Adventure Camp

1998-2002 Faith Pharmacy Volunteer

1992-1996 King of the Bluegrass Flag Football Tournament for Big Brothers/Big

Sisters

Documents

CURRICULUM VITAE David L. DeRemer, Pharm.D, FCCP, … · David L. DeRemer - CV 5 2015 PHRM 5210: Insights into Clinical Practice – 2 contact hours, ... 2012 Ahmed Al-Azayzih, Pharm.D